Holen Sie sich die Stockscreener-App
2.15
0.46%
-0.01
Handel nachbörslich:
2.13
-0.02
-0.93%
Schlusskurs vom Vortag:
$2.16
Offen:
$2.18
24-Stunden-Volumen:
76,294
Relative Volume:
0.06
Marktkapitalisierung:
$22.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.57M
KGV:
-0.3413
EPS:
-6.3
Netto-Cashflow:
$-38.56M
1W Leistung:
-1.83%
1M Leistung:
-17.31%
6M Leistung:
+22.86%
1J Leistung:
-6.52%
1-Tages-Spanne:
$2.09
$2.21
1-Wochen-Bereich:
$1.94
$2.2575
52-Wochen-Spanne:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Firmenname
Sab Biotherapeutics Inc
Sektor
Branche
Telefon
305-845-2813
Adresse
777 W 41ST ST, MIAMI BEACH
Vergleichen Sie SABS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.15 | 20.06M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-10-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-05 | Eingeleitet | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten
SAB Biotherapeutics Inc. Equity Warrant stock retracement – recovery analysis2025 Top Gainers & Risk Controlled Daily Trade Plans - Newser
What to do if you’re stuck in SAB Biotherapeutics Inc.CEO Change & Free High Return Stock Watch Alerts - Newser
Advanced analytics toolkit walkthrough for SAB Biotherapeutics Inc. Equity WarrantJuly 2025 Highlights & AI Forecast Swing Trade Picks - Newser
What MACD signals say about SAB Biotherapeutics Inc.2025 Price Targets & Breakout Confirmation Trade Signals - Newser
Exit strategy if you’re trapped in SAB Biotherapeutics Inc. Equity WarrantJuly 2025 Pullbacks & Low Drawdown Momentum Ideas - Newser
Can SAB Biotherapeutics Inc. hit a new high this monthSell Signal & AI Powered Market Entry Strategies - Newser
How hedge fund analytics apply to SAB Biotherapeutics Inc. Equity Warrant stockPredictable Income Summary for Long-Term Trades - Newser
How hedge fund analytics apply to SAB Biotherapeutics Inc. Equity Warrant stock [2025 Breakouts & Breakdowns]AI Driven Stock Reports - Newser
Key metrics from SAB Biotherapeutics Inc.’s quarterly dataShort-Term AI-Based Stock Price Forecast - Newser
Price momentum metrics for SAB Biotherapeutics Inc. explainedFree Capital Growth With Controlled Risk Picks - Newser
Measuring SAB Biotherapeutics Inc.’s beta against major indicesTechnical Reversal Pattern Summary and Tracker - Newser
Why SAB Biotherapeutics Inc. stock attracts strong analyst attentionSteady Return Plan Based on Data Analysis - Newser
Top chart patterns to watch in SAB Biotherapeutics Inc.Short-Term Sector Movement Forecast Generator - Newser
Applying Elliott Wave Theory to SAB Biotherapeutics Inc. Equity WarrantPredictive AI Engine for Smart Investing - Newser
How SAB Biotherapeutics Inc. Equity Warrant stock performs during market volatilityChart Based Entry Tool for ROI Traders - Newser
SAB Biotherapeutics Inc. stock chart pattern explainedFree Pattern Detection for Entry Confirmation - Newser
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attentionFree Quick Gain Stock Watch With Indicators - Newser
Can a trend reversal in SAB Biotherapeutics Inc. Equity Warrant lead to recoveryPredictive Screener for Daily Trade Watch - Newser
Technical analysis overview for SAB Biotherapeutics Inc. stockRisk Shielded Trade Watch with Analysis - Newser
Will SAB Biotherapeutics Inc. Equity Warrant continue its uptrendFree Short Term Buy List With Stop Protection - Newser
Predicting SAB Biotherapeutics Inc. Equity Warrant trend using moving averagesSafe Investment Ideas with Growth Upside - Newser
Analyzing net buyer seller activity in SAB Biotherapeutics Inc.Free Trade Setups With Clear Risk Limits - Newser
Will SAB Biotherapeutics Inc. stock benefit from interest rate changesFree Real Time Stock Movement Analysis - Newser
Sector ETF performance correlation with SAB Biotherapeutics Inc. Equity WarrantTrading Opportunities Forecast by AI Insight - Newser
Risk adjusted return profile for SAB Biotherapeutics Inc. Equity Warrant analyzedFree Trade Timing Strategy With Technical Data - Newser
Can swing trading help recover from SAB Biotherapeutics Inc. Equity Warrant lossesCapital Growth Plan for New Investors - Newser
Analyzing SAB Biotherapeutics Inc. with multi timeframe chartsCapital Growth Plan for New Investors - Newser
Ichimoku Cloud Indicates Uncertainty Around SAB Biotherapeutics Inc.Consistent Income Focused Trade List Analyzed - metal.it
What makes SAB Biotherapeutics Inc. Equity Warrant stock price move sharplyAI-Based Reversal Point Prediction Signal - Newser
SAB Biotherapeutics Inc. stock volume spike explainedMinimal Risk Growth Investment Opportunity Analysis - Newser
Chardan Capital Issues Pessimistic Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price - Defense World
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
Should you hold or exit SAB Biotherapeutics Inc. Equity Warrant nowLong-Term Investment Strategy Summary Guide - Newser
What the charts say about SAB Biotherapeutics Inc. todayValue Holding Return Summary With Outlook - Newser
Is SAB Biotherapeutics Inc. Equity Warrant Stock a Smart Buy in 2025 Investment Analysis InsideMulti-Bagger Detection with Trend Tools - Newser
Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20 - Investing.com Canada
SAB Biotherapeutics: Chardan Capital Maintains Buy Rating with Lower PT of $12 - AInvest
SAB Biotherapeutics 2024 Q4 Earnings Significant Loss Widening Despite Revenue Decline - AInvest
What high frequency data says about SAB Biotherapeutics Inc. Equity WarrantDownside Risk Evaluation and Stock Analysis - Newser
SAB Biotherapeutics Reports Increased Losses Amid Funding Boost - TipRanks
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics Secures $175M Funding, Paving Way for Phase 2b Diabetes Trial and Justifying Buy Rating - TipRanks
SAB Biotherapeutics Expected to Beat Earnings Estimates Ahead of Q2 Release. - AInvest
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year - TipRanks
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):